Experimental pill promises new hope for deadly pancreatic cancer
The once-daily pill cut the risk of death by 60% and caused fewer severe side effects in 500 trial patients.
- On Sunday, researchers at the American Society of Clinical Oncology annual meeting in Chicago presented results for the experimental pill daraxonrasib, which significantly extended survival for patients with advanced pancreatic cancer.
- Mutations in the KRAS gene drive over 90% of pancreatic tumors, but these proteins were long considered 'undruggable' because they lacked the molecular pockets required for traditional drug binding.
- The Phase 3 trial of 500 patients showed a median overall survival of 13.2 months for those taking daraxonrasib, compared to 6.7 months for chemotherapy recipients, with fewer severe side effects reported.
- Revolution Medicines is pursuing formal U.S. Food and Drug Administration approval, while the agency currently allows 'expanded access' to the medication for eligible patients who cannot wait.
- Oncology experts believe this 'landscape-changing' breakthrough could eventually help treat other RAS-driven cancers, though researchers emphasize that daraxonrasib is a significant step forward rather than a cure.
222 Articles
222 Articles
The publication of two studies, with the impressive results against cancer achieved by the new generation immunotherapy drugs amibandatamab and daraxonrasib, caused a global wave of optimism.
What to Know About the New Pancreatic Cancer Drug That Doubles Survival Time
Fact checked by Nick BlackmerA new drug shows promise as a treatment for pancreatic cancer, one of the deadliest cancers.Credit: ljubaphoto / Getty ImagesA phase 3 clinical trial found that daraxonrasib shows promise as a treatment for pancreatic cancer.The drug doubled survival time and improved quality of life for people with advanced disease.The findings represent a potential breakthrough in pancreatic cancer treatment.Pancreatic cancer is on…
Scientists finally crack an “undruggable” pancreatic cancer target and nearly double survival
For decades, pancreatic cancer has been one of the most lethal cancers, with few effective treatment options. A new drug, daraxonrasib, targets the KRAS mutation that fuels most pancreatic tumors—something many scientists once thought couldn't be done. In a major clinical trial, the treatment nearly doubled survival for patients with advanced disease and reduced the risk of death by 60%.
Dnevni list Danas
nin.rsThe effectiveness of the new drug daracsonrasib encourages scientists that the treatment of one of the deadliest types of cancer could be improved.
Coverage Details
Bias Distribution
- 49% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
